215 results
Page 6 of 11
8-K
EX-99.1
k1818gryhgdknczh
10 Mar 21
VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902
7:38am
8-K
EX-99.1
6gy 66sxj
2 Feb 21
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI’s 3-Antigen Prophylactic Hepatitis B Vaccine
8:21am
8-K
EX-99.1
2fxw ur3seznwq
15 Jan 21
VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI’s
8:24am
8-K
EX-99.1
itfmsd
23 Dec 20
VBI Vaccines Announces European Medicines Agency Acceptance of Marketing
11:21am
8-K
EX-99.1
htutc8ued7ifafezzv
7 Dec 20
VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine
10:23am
8-K
EX-99.1
nv8g5 lrm1bo
1 Dec 20
VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine
8:16am
8-K
EX-99.1
69u yf7db8
23 Nov 20
Other Events
1:20pm
8-K
EX-99.2
m7dankz
19 Nov 20
Regulation FD Disclosure
8:00am
8-K
EX-99.1
bda 8pgypu
18 Nov 20
VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B
8:55am
8-K
EX-99.1
zn4efooc9wh6 og37
9 Nov 20
VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
9:12am
8-K
EX-99.1
bbdn5tqagxj6k9
2 Nov 20
VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update
11:31am
8-K
EX-99.1
dh5qer
24 Sep 20
VBI Vaccines to Present at Upcoming Scientific Conferences
8:00am
8-K
EX-99.2
tk1lw t4jpszpdn8y
17 Sep 20
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
nbhbc0dj
14 Sep 20
VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
9:27am
8-K
EX-99.1
s61nl
31 Aug 20
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
8:44am
8-K
EX-99.1
8t1tab0zacyolgeza6
21 Aug 20
VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020
11:13am